NSEInvestor Presentation6d ago · 14 Aug 2026, 02:59 pm
Investor Presentation
Hexagon Nutrition Limited · HEXAGON
✦ AI SummaryResults
Hexagon Nutrition Limited has informed the Exchange about Investor Presentation for Q1 FY27 results, including unaudited financial results and a presentation detailing the company's overview, product portfolio, manufacturing, industry overview, financial performance, growth strategy, and management.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Hexagon Nutrition Limited has informed the Exchange about Investor Presentation
Attachments (1)
📄pdf
Download →
HEXAGONNUTRITION_14082026145906_HNL_IR_presentation_with_cover-final.pdf
View document text
HEXAGON NUTRITION LIMITED
'Nutritionally Yours...
Ref: HNL/SEC/2026-27/20 Date: 14th August 2026
Na(cid:415)onal Stock Exchange of India Limited BSE Limited
Lis(cid:415)ng & Compliance Department Lis(cid:415)ng Department
Exchange Plaza, C-1, Block G, Floor 25, P J Towers,
Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400001
Mumbai – 400051, Maharashtra, India. Maharashtra, India.
SYMBOL: HEXAGON Scrip Code: 544785
Dear Sir/Madam,
Ref: HEXAGON NUTRITION LIMITED - ISIN: INE0JUI01012
Subject: Disclosure Under Regulation 30 Of Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) – Q1 FY27 - Result Presentation
Pursuant to the provisions of Regulation 30 of the Listing Regulations read with Para A (15)(a) of Part A of
Schedule III thereto, In continuation to our letter dated 10th August 2026 regarding intimation of Earnings
Call of the Company scheduled on Friday, 14th August 2026 at 04:00 p.m. to discuss the Unaudited
Financial Results (Standalone & Consolidated) of the Company for the quarter ended on 30th June 2026,
kindly find enclosed herewith Presentation for Q1FY27 Result of the Company.
The above disclosure is also being made available on the website of the Company at
www.hexagonnutrition.com
This is for your information and records.
Yours faithfully,
For Hexagon Nutrition Limited
Vedanti Vartak
Company Secretary and Compliance Officer
ICSI Membership No.: A41580
CIN:- L24110MH1993PLC072189 Nashlk Plant :
Registered Office : Plot No. 92 & Plot No. 447, Unandanagar, Lakhamapur,
404 Global Chamber, Ada rsh Nagar, Link Road, Dlndorl, Naslk - 422 202, Maharashtra, lndla
Andherl (W), Mumbai, Maharashtra - 400053, lndla
Tel, No.: +91-22-62136710/711 Chennal Plant :
Website : www.hexagonnutrltlon.com Plot No. B11, Phase - 1 MEPZ-SEZ, Tambaram,
Emall ID: enqulry@hexagonnutrltlon.com Chennal - 600 045, Tamll Nadu, India
Investor Presentation Q1 FY27
STRENGTH IMMUNITY ENERGY
Disclaimer
This presentation has been prepared by Hexagon Nutrition Limited, solely to provide information about the Company to its stakeholders. No representation or
warranty,expressorimplied ismadeasto,andnoreliance shouldbeplacedon,thefairness,accuracy,completenessor correctnessof suchinformationoropinions
containedherein.NoneoftheCompanynoranyofitsrespectiveaffiliates,advisersorrepresentatives,shallhaveanyliabilitywhatsoever(innegligenceorotherwise)
foranylosshowsoeverarisingfromanyuseofthispresentationoritscontentsorotherwise arisinginconnectionwiththispresentation.
The information contained in this presentation is only current as of itsdate. The Company may alter, modify or otherwise change in any manner the content of this
presentation, without obligation to notify any person of such revision or changes. Certain statements made in this presentation may not be based on historical
information or facts and may be "forward-looking statements", including those relating to the Company’s general business plans and strategy, its future financial
condition and growth prospects, and future developments in its industry and its competitive and regulatory environment. Actual results may differ materially from
these forward-looking statements due to number of factors, including future changes or developments in the Company’s business, its competitive environment,
informationtechnologyandpolitical,economic,legalandsocialconditionsinIndia.
PleasenotethatthispresentationisbasedonthepubliclyavailableinformationincludingbutnotlimitedtoCompany’swebsiteandAnnualReports.
This communication is for general information purposes only, without regard to specific objectives, financial situations and needs of any particular person. Please
notethatinvestmentsinsecuritiesaresubjecttorisksincludinglossofprincipalamount.
Thispresentationdoesnotconstituteanofferorinvitationtopurchaseorsubscribeforanysharesinthecompanyandneitheranypartofitshallformthebasisofor
berelieduponinconnectionwithanycontractorcommitmentwhatsoever.
01 COMPANY OVERVIEW 02 PRODUCT PORTFOLIO & BRANDS
Snapshot, evolution, vision, and business Pentasure, Pediagold, Obesigoand
model more
TABLE OF
03 MANUFACTURING & R&D 04 INDUSTRY OVERVIEW
CONTENTS
Plants, capacity, certifications, and Market size, tailwinds, and competitive
innovation landscape
FINANCIAL PERFORMANCE GROWTH STRATEGY & OUTLOOK
05 06
Revenue, EBITDA, PAT, balance sheet Organic growth, new categories,
global expansion
MANAGEMENT & GOVERNANCE APPENDIX
07 08
Promoters, board, leadership team Financial statements, certifications, awards
COMPANY
OVERVIEW
Indian Nutrition Market
Industry trends
RAPID GROWTH DRIVERS
Rising health awareness, higher disposable incomes, and
supportive government policies are propelling demand
across dietary supplements, functional foods, and medical
nutrition.
DIVERSE CONSUMER BASE
Nutritional needs vary regionally —North India favors
protein and multivitamin products, while South India
focuses on diabetes and hypertension supplements.
MARKET OUTLOOK & CHALLENGES
India ranks among the top global nutrition markets;
however, affordability, misinformation, and regional gaps
persist —requiring innovation, education, and accessibility
initiatives.
Younger Consumers Prioritise wellness, Older Consumers Managing chronic
spending through trusted, medically conditions, spending through trusted,
backed products. medically backed products.
Company Snapshot
One Company. Full Nutrition Spectrum
Research-driven, pure-play nutrition company
spanning the full value chain — from micronutrient
premixes to therapeutic and clinical products —
under one integrated platform.
₹1,043 Mn ₹118 Mn ₹81 Mn
Founded 1993 · Mumbai, Maharashtra
Q1 FY27 Revenue Q1 FY27 EBITDA Q1 FY27 PAT
Employees 527+ permanent staff Margin: 11.3% Margin: 7.7%
Mfg. Plants 4 (Nashik, Chennai, Thoothukudi, Uzbekistan)
R&D Centres 2 (Nashik + Chennai)
Countries 80+ export markets
Distributors 358 domestic + 20 international
Certifications FSSC 22000, ISO 9001, GMP, Halal
Corporate Evolution — 30+ Years of Building India's
Nutrition Leader
Hong Kong &
Founded ICAR UNICEF Nutrone ₹3,000+ Mn
Uzbekistan
Nashik plant · Approval received for Production approval for Incorporated wholly owned New brand launch · Annual revenue
Micronutrient food testing the MNP incorporated Asia-Pacific & Everyday nutrition milestone crossed
formulations laboratory central Asia
1993 2004 2013 2017 2018 2019 2020 2022 2023 2024 2025 2026
Chennai Plant DSIR R&D South Africa Amalgamation of NRPL Certificate of recognition
2nd manufacturing DSIR approval – WOS incorporated · - with HNL Certificate of B2C revenue
facility · Export focus Chennai R&D Facility Africa expansion recognition being milestone
part in Dun and crossed 100 cr&
Bradstreet Global Listed on NSE &
Database BSE -June 2026
and Merger of
HNEPL Chennai
with HNL
Vision, Mission & Values
VISION MISSION
To improve human health and nutrition through
To be a globally recognized, research-driven nutrition
innovative, affordable, and high-quality products
company —the partner of choice for individuals,
across wellness, clinical nutrition, food fortification,
healthcare professionals, FMCG leaders, and
and humanitarian nutrition — delivered with
humanitarian organizations seeking science-backed
consistency and care.
nutritional solutions.
QUALITY WITHOUT INTEGRITY &
CUSTOMER PARTNERSHIP
COMPROMISE SCIENCE FIRST INNOVATION GOVERNANCE SOCIAL IMPACT
Long-term relationships with FSSC 22000, GMP, ISO 9001, Every product grounded in 9 products in R&D pipeline. Listed entity. Independent UN-licensed MNP supplier.
FMCG majors, hospitals, and Halal, Intertek/GAIN certified nutritional science and Active new category entry directors. Audit committee. Addressing malnutrition in
UN agencies. 55% repeat across all plants. clinical evidence. DSIR- strategy. Continuous Professional management 80+ countries. Aligned with
customers. approved R&D centres. formulation upgrades. team. SDG goals.
Our Pu
[Showing first 8,000 characters — download PDF for full document]